

Case 1

Table 1 NEXUS chest criteria

Age >60 years
Rapid deceleration mechanism [fall >6 meters (20 feet) or motorized vehicle accident >65 km (40 miles) per hour]
Chest pain
Intoxication
Distracting injury
Tenderness to chest wall palpation
Abnormal alertness/mental status

NEXUS, National Emergency X-radiography Utilization Studies.

Table Title

Table Body

Table Footnote

Case 2

Table 2 Clinic trials of checkpoint inhibitor therapy in hepatobiliary cancers

Agents	Cancer Type	Patient Population	Immunotherapy Target (s)	Phase	ClinicalTrials.gov Locator
Tislelizumab	HCC	Advanced	PD-1	Phase III	NCT03412773
Durvalumab and Tremelimumab	HCC	Advanced	PD-L1 and CTLA-4	Phase III	NCT03298451
Atezolizumab and Bevacizumab	HCC	Advanced	PD-L1	Phase III	NCT03434379
Pembrolizumab plus lenvatinib	HCC	Advanced	PD-1	Phase III	NCT03713593
Nivolumab and Ipilimumab	HCC	Advanced	PD-1 and CTLA-4	Phase III	NCT04039607
Nivolumab	HCC	Adjuvant	PD-1	Phase III	NCT03383458
Pembrolizumab	HCC	Adjuvant	PD-1	Phase III	NCT03867084
Durvalumab and Bevacizumab	HCC	Adjuvant	PD-L1	Phase III	NCT03847428
Durvalumab	BTC	Advanced	PD-L1	Phase III	NCT03875235
Pembrolizumab	BTC	Advanced	PD-1	Phase III	NCT04003636
M7824	BTC	Advanced	PD-L1	Phase III	NCT04066491
KN035	BTC	Advanced	PD-L1	Phase III	NCT03478488
Nivolumab and TACE	HCC	Localized	PD-1	Phase II	NCT03572582
Nivolumab and Y90	HCC	Advanced	PD-1	Phase II	NCT03033446

HCC, hepatocellular carcinoma, BTC, biliary tract cancer, TACE, trans-arterial chemoembolization; Y90, Yttrium-90.

Table Title

Table Head

Table Body

Table Footnote

Case 3

Table 1 FDA approvals for Immunotherapy in HCC and BTC in United States

Immunotherapy FDA	HCC		BTC		HCC and BTC	
	Approval	Date	Approval	Date	Tumor Agnostic Approval (MSI-high)	Date
Nivolumab	Yes	Sep 22, 2017	No	N/A	No	N/A
Pembrolizumab	Yes	Nov 9, 2018	No	N/A	Yes	May 23, 2017

HCC, hepatocellular carcinoma; BTC, biliary tract cancer; N/A, not applicable.

Table Title

Table Head

Table Body

Table Footnote